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Abstract: Cognitive impairment is strongly associated with functional outcomes in psychiatric
patients. Involvement of n-3 long chain polyunsaturated fatty acid (n-3 LC-PUFA), in particular
docosahexaenoic acid (DHA), in brain functions is largely documented. DHA is incorporated into
membrane phospholipids as structural component, especially in the central nervous system where
it also has important functional effects. The aim of this review is to investigate the relationship
between DHA and cognitive function in relation to mental disorders. Results from few randomized
controlled trials (RCTs) on the effects of DHA (alone or in combination) in psychotic, mood and
neurodevelopmental disorders, respectively, suggest that no conclusive remarks can be drawn.
Keywords: n-3 long chain polyunsaturated fatty acids; docosahexaenoic acid; psychiatric disorders;
cognition; cognitive symptoms
1. Introduction
The growing number of studies on the association of n-3 long chain polyunsaturated fatty acids
(n-3 LC-PUFAs) on cognitive function and mental health, especially psychiatric illness, published in
the last decades reflects growing interest in this area of research. Given the global market for n-3
PUFA products, it is of public importance that there is a more conclusive picture as to whether their
supplementation improves cognitive performance. Therefore, we conducted a review of randomized
placebo-controlled trials (RCTs) which examined the role of n-3 PUFAs, in particular docosahexaenoic
acid (DHA), in maintaining or in treating cognitive functions in different mental disorders. Cognitive
functioning can be defined as a collection of different abilities including memory, language, attention,
perception, problem solving and mental imagery. These cognitive and practical competencies are the
key to enhancing individual and community well-being and to living a life of purpose [1]. Cognition
can be sub-divided into different domains. According to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) [2] there are six key domains: complex attention, executive function,
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learning and memory, language, perceptual-motor, and social cognition. Each cognitive domain
is divided into several more specific cognitive subtypes (Figure 1). Attention can be considered a
fundamental cognitive domain because it permits one to accept, recall and maintain different and
complex information. More specifically, complex attention comprises several abilities, including the
capacity to sustain attention, the capacity to selectively maintain attention to a specific stimulus, the
capacity to shift attention, and the capacity to put attention to various stimuli at the same time [2,3].
Similarly, executive functions include as sub domains planning, decision making, working memory,
responding to feedback, inhibition, and flexibility [2]. Moreover, learning and memory represent
mental functions that allow people to acquire, retain, and recall new impressions, information and
sensations after they have been experienced. Memory can be divided into three stages: sensory,
short-term and long-term. Information processing starts with sensory memory, moves to short-term
memory and eventually transfers to long-term memory. Then, the function of long-term memory is
to store data through various categorical models or systems [4]. Interestingly, within the cognitive
domains there is also language, which can be defined as the capacity of naming, word searching,
grammar using, and comprehension; more specifically two different aspects of language are identified
as expressive and receptive [2]. Another cognitive domain is the perceptual-motor function comprising
visual perception, visuospatial-construction, perceptual-motor coordination, and performance [2].
The dysfunction of the perceptual-motor domain, occurring for example with neurologic injury, can
result in apraxias, agnosia, hemineglect, and Balint syndrome [5]. Finally, the last cognitive domain
is social cognition, which is the ability to recognize emotions in social situations, to have a theory
of mind, to feel empathy, to make an attributional style, and to have an insight into something. It is
involved in social and vocational functioning and interpersonal relationships [6].
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1.1. Cognitive Impairment in Psychiatric Disorders
Cognitive impairments are reported as one of the main features of psychiatric disorders and
they have a major negative impact on psychosocial functioning of patients [7,8]. Indeed, several
mental disorders, such as major depressive disorder (MDD), bipolar disorder (BD), schizophrenia
(SZ), attention deficit/hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), and
obsessive-compulsive disorder (OCD) were consistently found to have impairments in cognitive
functions involving verbal memory, executive functions, attention and processing speed, with different
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levels of severity [3,9–11]. Specifically, in MDD cognitive dysfunctions have been observed to persist
despite remission of mood symptoms, suggesting an independence of cognitive symptoms compared
to depressive symptoms [9,12,13]. However, individuals with SZ are much more likely to exhibit
severe cognitive impairment than individuals with BD, and good cognitive functioning is more
often observed in BD patients than in SZ patients [14]. Indeed, schizophrenia (SZ) represents one
of the most severe and disabling mental disorders affecting 1% of the general population, which is
characterized by a) positive symptoms, such as delusions, hallucinations, disorganization in thought
or behaviors; b) negative symptoms, including flat affect, apathy, social withdrawal, poverty of
thinking and speech; and c) cognitive symptoms, including poor executive functioning, difficulty
maintaining attention and disturbance of working memory [2]. Moreover, different theories have
been proposed to explain the neurobiological basis of cognitive impairment but none of them
are completely comprehensive. Between these theories we found the neurodegeneration model
correlated to dysregulation of the immune-inflammatory system, variations in the tryptophan catabolite
(TRYCAT) pathway, dysregulation of glutamate signaling, reductions of neurotrophic elements such as
brain-derived neurotrophic factor (BDNF) [15–18]. So, considering the lack of a clear biological basis
for cognitive dysfunction in psychiatric disorders and the uncertain positive effect of antipsychotic,
antidepressant/mood stabilizer drugs on cognitive impairment [9,19,20], there is a growing interest
to find different neuroprotective and pro-cognitive agents for these disorders [21]. In this regard, the
scientific community has recently driven attention towards the study of the ameliorating effects of
nutrients and dietary supplementations on cognition by means of compounds that may be collectively
named under the umbrella term of “functional nutrients”.
1.2. Fatty Acids: The Biologic Plausibility of Docosahexaenoic Acid (DHA)
Among functional nutrients, n-3 polyunsaturated fatty acids (n-3 PUFAs) have been proposed
as therapeutic supplements for a wide range of diseases as well as certain symptoms. Due to their
pleiotropic properties, n-3 PUFAs are currently under investigation as a treatment for arteriosclerosis,
cancer, diabetes, hypertension, arthritis, dementia, psychiatric disorders and some autoimmune
diseases [22]. In the last two decades, there is accumulating evidence about the neuroprotective
functions of LC-PUFAs, in particular docosahexaenoic acid (DHA), which is a n-3 LC-PUFAs together
with eicosapentaenoic acid (EPA) and α-linolenic acid (ALA, the parental essential fatty acid of the n-3
series), as well as the n-6 LC-PUFA linoleic acid (LA), which is the essential parental n-6 fatty acid that
is as an important constituent of neuronal membrane. ALA and LA are normally found in plant oils
(e.g. walnut, edible seeds, clary sage seed oil, algal oil, flaxseed oil) while DHA and EPA are commonly
found in marine oils (e.g. fish oils, eggs, krill oil). Marine algae and phytoplankton are primary sources
of n-3 LC-PUFAs. LA and ALA from plants are the precursors (as previously indicated) of n-6 and n-3
LC-PUFAs, respectively. In human tissues, LA is converted mainly to arachidonic acid (AA), ALA to
EPA and then less efficiently to DHA [23].
LC-PUFAs, particularly DHA and AA, are incorporated into cell membrane phospholipids and,
apart from their structural role in these membranes, they can also modify the structure of the cell
membrane and the function of membrane proteins acting as precursors of autocoid signaling molecules
(e.g. docosanoids) and as potent activators of a number of gene transcription factors (e.g., peroxisome
proliferator activated receptors). The most important role of n-3 LC-PUFAs is generally linked to
the incorporation of DHA, in exceptionally high levels, in membranes of the central nervous system.
Indeed, DHA is found in significant concentrations in the retinal and synaptic membranes due to its
high fluidity [24].
Generally, the membrane structure of PUFAs—where the principal components are represented
by LA, AA and DHA—seems to be more receptive to DHA coming from the diet than from the intake
of LA and AA [25]. Moreover, data from animal models have shown that the increase of ALA from
diet is directly proportional to membrane n-3/n-6 PUFA-ratios at LA/ALA intakes of <10. Instead, the
dietary balance between ALA and LA influences slightly higher ALA intakes, and a similar biphasic
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response is also seen in diets that are rich in PUFAs [26]. These data demonstrate the high sensitivity of
tissue membranes to variations in dietary PUFA supplies within the normal range, strongly preferring
the inclusion of n-3 LC-PUFAs over LA and AA. Consequently, n-3 PUFAs seem to be the key element
of membrane PUFAs composition and unsaturation. Indeed, the accumulation of DHA in membrane
phospholipids cells of different tissues, e.g., erythrocytes (RBC), has been demonstrated to be related
to diet, principally fish intake and breastfeeding during infancy, even though another small source
of DHA is that formed endogenously by the desaturation and elongation of ALA. This biochemical
process of conversion is limited by the delta-6 desaturase enzymatic step, which is normally less
efficient, but the rate conversion has been shown to be influenced by the individual asset of the
haplotypes, including single-nucleotide polymorphisms (SNPs), associated with PUFA metabolism.
Indeed, in addition to diet, common polymorphisms in the fatty acid desaturase (FADS) gene cluster
have very marked effects on LC-PUFA status [27].
For all these reasons, n-3 LC-PUFAs are considered to be one of the most important components
of cell membranes, especially neurons, especially because they are implicated in the regulation of cross
talk between cells and in metabolic processes of energy transformation.
Additionally, LC-PUFAs are essential components for infant and child neurodevelopment because
they are implicated in many neuronal processes (e.g. the regulation of membrane fluidity and gene
expression) [27]. The accumulation of DHA in the brain starts in utero, especially during the second
half of pregnancy, when DHA and AA accrue rapidly in the grey matter of the brain continuing
up to two years of age and the high levels of DHA in the brain are maintained throughout life [28].
With respect to the functional effects of LC-PUFA supplementation in infancy, the most accepted
developmental effect is an increased rate of visual acuity development [29]. Moreover, a deficiency or
imbalance of n-3/n-6 LC-PUFAs has been associated with poorer child neurodevelopment in cognitive
domains such as language (e.g. verbal fluency) and motor skills (e.g. gross and fine motor abilities) [30].
A growing body of evidence shows that diets with a lower intake of n-3 PUFAs, including EPA
and DHA, are associated with the pathophysiology of different mental disorders [31]. On the contrary,
cross-national epidemiological studies suggest that greater habitual dietary intake of fish/seafood,
primary dietary sources of preformed EPA and DHA, are associated with reduced lifetime prevalence
rates of affective disorders [32,33]. A meta-analysis of controlled trials suggested that short-term
fish oil supplementation, especially with higher doses of EPA, is more effective than placebo to
produce a beneficial overall effect in major depressive disorder patients [34]. Emerging translational
evidence additionally suggests that DHA is required for normal brain development [27]; for this
reason, a decrease in LC-PUFAs could have negative effects on cognitive function [35]. One possible
explanation of the positive correlation between optimal DHA status and cognition may be due to the
fact that during development, one of the most responsive cerebral areas to DHA supplementation
is the frontal cortex [36]. The frontal lobes have a key role in executive and higher-order cognitive
functions, including sustained attention, planning and problem solving [37], as well as for social,
emotional and behavioural development [38]. Therefore, an optimal lipid DHA composition may
not only be important during the development and maturation of the brain from pregnancy to
childhood/adolescence but could also contribute to maintain cognitive efficiency during the entire
lifespan and ameliorate the aging of the adult’s brain [39,40]. Indeed, in the last decades, there
is accumulating evidence suggesting neuroprotective properties of n-3 LC-PUFAs, in particular
DHA. Also, observational and clinical randomized trials have shown an association between high
(“optimal”) levels of n-3 LC-PUFAs and a lower incidence of mental illnesses, such as depression [41,42].
Observational studies [43,44] showed a link between abnormalities in membrane fatty acid levels and
the cognitive impairment in ultra-high-risk subjects for psychosis and in schizophrenic patients.
Interestingly, a positive and significant correlation was found between the Brief Assessment of
Cognition in Schizophrenia (BACS) composite score and blood EPA and DHA levels, while a negative
and significant correlation was shown between a daily dose of antipsychotic medication, blood DHA
levels and the BACS composite score. Moreover, neuroimaging studies also supported the positive link
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between n-3 PUFAs levels and mood functioning. Indeed, a structural Magnetic Resonance Imaging
(MRI) study reported that individuals with higher dietary intake levels of n-3 PUFAs have greater grey
matter volume in the anterior cingulate cortex, the right hippocampus, and the right amygdala, which
are key areas involved in mood regulation and cognition [45].
2. Materials and Methods
A comprehensive search on PUBMED of all trails using DHA on cognitive functions in psychiatric
disorders published up to November 2018 was performed.
Articles of potential interest were identified by using the following search terms: “omega-3“,
“n-3 long-chain polyunsaturated fatty acids”, “n-3 LCPUFAs”, “DHA”, “docosahexaenoic acid”,
combined with the following term: “psychiatric disorders”, “mental diseases”, “psychotic disorders”,
“ psychosis”, “ultra-high risk psychosis”, “schizophrenia”, “bipolar disorder”, “major depressive
disorder”, “affective disorder”, “depression”, “ personality disorder”, “ anxiety disorders”, “obsessive
compulsive disorders”, “eating disorders”, “ADHD”, “autism” AND “ “cognitive functions”,
“cognitive symptoms”, “cognition”. In this review, trials examining the efficacy of DHA on cognitive
functions in psychiatric disorders were selected.
We considered only trials in which the authors used an exposure of DHA alone or combined
with EPA as a unique treatment or as an adjunctive therapy to other drugs (e.g., antipsychotic,
antidepressants, mood stabilizers and benzodiazepines), or other no pharmacological strategies such
as psychotherapy and physical exercise compared to placebo or pharmacotherapy alone.
To limit the heterogeneity of this review and to reduce selection biases, we decided to exclude
trials examining the efficacy of others n-3 LCPUFAs (e.g. EPA) in subjects with psychiatric diagnosis;
trials analyzing serum levels of DHA as primary outcome; studies that did not explore the effects of
DHA on cognitive functions or cognitive symptoms as primary outcome.
In addition, we excluded trials that employed a diet enriched in DHA as a supplementation.
Among the 1114 articles retrieved, 198 studies were identified and screened by reading the abstract,
and, when necessary, the full text, in order to select those articles relevant for the analysis. A manual
search of bibliographic cross-referencing complemented the search. Reference lists of relevant papers
were also inspected to identify any additional trials.
Relevant articles were obtained and included in the review if (a) they reported an exposure
to DHA; (b) included cognitive functions and cognitive symptoms as an outcome measure; and
(c) enrolled human participants and reported a trial.
The process of identification and inclusion of trials is summarized in Figure 2. Finally, 8 trials
were included for the review. All searches, trial identification, data abstraction, and tabulation were
completed independently by three researchers. Discordances were discussed and resolved.
Nutrients 2019, 11, 769 6 of 17
Nutrients 2019, 9, x FOR PEER REVIEW  6 of 19 
 
Figure 2. PRISMA diagram: docosahexaenoic acid (DHA) supplementation in psychiatric disorders. 
3. Results 
3.1 DHA and Psychotic Disorders 
Many data showed that cognitive symptoms are often an early marker and a potential 
predictor of outcome of illness in schizophrenia [46]. It is worth mentioning that approximately in 
75%–85% of SZ patients showed cognitive deficits, especially in memory abilities [47]. Moreover, 
cognitive deficits have been found to be present already at the onset of illness and even in ultra-
high risk (UHR) individuals [48,49] and in unaffected family members of patients [50,51], ultimately 
suggesting an important genetic contribution. While many theories regarding SZ pathogenesis have 
been proposed, the majority of the studies focused on neurotransmitter function, especially on 
abnormalities of dopamine activity. However, antipsychotic treatments based on dopamine 
hypothesis of schizophrenia have showed only a partial efficacy, and current drugs fail to alleviate 
symptoms in 30%–60% of patients. An alternative idea, postulated in 1970s, proposed a 
Figure 2. PRISMA diagram: docosahexaenoic aci ( A) supplementation in psychiatric disorders.
3. Results
3.1. DHA and Psychoti D sorde s
Many data showed that cognitive symptoms are often an early marker and a potential predictor
of outcome of illness in schizophrenia [46]. It is worth mentioning that approximately in 75%–85%
of SZ patients showed cognitive deficits, especially in memory abilities [47]. Moreover, cognitive
deficits have been found to be present already at the onset of illness and even in ultra-high risk (UHR)
individuals [48,49] and in unaff cted family members of patients [50,51], ultimately uggesting an
important genetic contribution. While many the ries regarding SZ pathoge esis have been proposed,
the majority of the studies focused on neurotransmitter function, especially on abnormalities of
dopamine activity. However, antipsychotic treatments based on dopamine hypothesis of schizophrenia
have showed only a partial efficacy, and current drugs fail to alleviate symptoms in 30%–60%
of patients. An alternative idea, postulated in 1970s, proposed a “phospholipid hypothesis” by
which SZ could be considered a disorder of membrane phospholipid metabolism [52,53]. According
to this theory, an increased activity of a phospholipase A2 (PLA2), which is a lipolytic enzyme,
implicated a progressive and important loss of polyunsaturated fatty acids in neuronal membranes.
This modification of membranes’ properties produced many biochemical abnormalities, such as
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reduced vasodilator responses to niacin and histamine and altered immunological functions. The final
effect in the central nervous system is a membrane alteration that might be enough to produce the
most serious consequences, since the brain needs co-ordinated sequential and parallel activities of
millions of neurons. This hypothesis goes through abnormalities of n-6 fatty acids such as AA and
of n-3 polyunsaturated fatty acids, such as DHA and EPA. In fact, many studies have shown a
reduction of AA, DHA and EPA in the red blood cells (principal recognized markers for essential
fatty acid status in the brain) of SZ patients [54,55]. Similarly, other studies also demonstrated that
SZ patients had a depletion of PUFAs in plasma, thrombocytes and post-mortem tissue [56], as well
as an elevation of membrane phospholipase A2 activity according to elevated membrane turnover
of PUFAs [57]. Interestingly, the negative symptoms of SZ patients seem to be especially linked to
severely abnormal levels of arachidonic acid and docosahexaenoic acid in red blood cell membrane
phospholipids [58]. Overall, these studies reported several different alterations in neuronal membrane
biochemistry, supporting the membrane hypothesis of schizophrenia in both chronic and first episode
SZ patients [59]. In particular, SZ patients at the first episode often showed an increase in phospholipid
membrane breakdown products within the brain [60], and this data is consistent with excitotoxic neural
membrane breakdown and reduced levels of membranes phospholipid precursors, often observed in
SZ [61]. We have then carried out a review of all randomized clinical trial studies (RCTs) with the final
aim of providing a clearer picture of the impact of DHA in schizophrenic subjects and in ultra-high-risk
(UHR) psychosis patients. Recent studies showed that early treatment of the prodromal period
of psychotic disorders seems to be linked to more favourable outcomes [62]. Interestingly, among
these treatments, n-3 PUFAs have been found to have potential beneficial impact due to their low
incidence of adverse effects. To date, only four RCTs explored the role of n-3 PUFAs supplementation
in UHR patients, but none of them investigated the cognitive effects of DHA as primary or secondary
outcomes. Second, we explored clinical trials administering n-3 PUFAs versus placebo in schizophrenia
patients for cognitive functioning but we found only two studies (one open label and one randomized
controlled trial) using only EPA for supplementation [63,64] and none using DHA alone or combined
with EPA, with contrasting results. In conclusion, taken all together these data suggested that no RCTs
exploring the effect of DHA alone or with other n-3 PUFAs (EPA) or n-6 PUFAs have been conducted
to investigate cognitive functioning in schizophrenic patients.
3.2. DHA and Mood Disorders
Bipolar disorder (BD) is a chronic mental illness characterized by recurrent episodes of mood
alterations (depressed or maniacal features) [65], with several consequences on social and cognitive
functioning [66]. Prevalence in general population ranges 2% to 3% considering the whole bipolar
spectrum disorder [67]. Furthermore, it also affects patient’s families, with high health-related costs,
medical morbidity and premature mortality [68]. A large number of BD patients (around 40% to
60%), present with cognitive impairments that impact everyday functioning, not only during maniacal
or depressive episodes, but also during euthymia [69]. Patients with BD also have deficits in social
skills, in fact the theory of the mind is clearly altered in maniacal phases but also altered in bipolar
euthymic patients, and the same cognitive deficits could make the performance of social cognition
worse [70]. Several factors related to the history of the bipolar disease seems to have a negative impact on
memory performance and executive function, in particular, illness duration and severity of symptoms [71].
Moreover, a high number of mood episodes seems to be a predictor of poor performance in several
cognitive domains. Scientific evidence underlined the presence of cognitive deficits in BD, also in remitted
patients [72]. The intensity of the neuropsychological disturbances varies according to the severity of the
disease; interestingly several findings indicate that people with BD II also show cognitive deficits of the
same form, but slightly less severe than those observed in BD I. Cognitive deficits can be observed even
before the onset of mental disease and executive functions seem to predict BD onset better than IQ [73].
Moreover, executive functions and other cognitive processes have been reported as being impaired in
adults and youth with BD, even during remission [74]. Beyond executive functions, the most frequently
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compromised cognitive domains are attention, memory and verbal learning [75]. Therefore, longitudinal
studies as well meta-analysis consistently reported the presence of cognitive deficits in BD, regardless
of mood phase, ultimately suggesting that the assessment of cognition could contribute to a better
understanding of the patient’s situation, pointing out possible vulnerabilities other than psychiatric
symptoms. Since in BD patients’ clinically relevant deficits in cognition are often present, we could
expect that a vicious loop to occur, given that executive function deficits may contribute to emotional
dysregulation, which in turn would contribute to a decay in cognitive performance [76].
Many data, including functional and MRI (magnetic resonance imaging) and PET (positron
emission tomography) studies, indicate the close link between emotion and cognition in BD;
particularly neural activation deficits are shown in regions involved in responding to salient stimuli
(amygdala, ventral striatum) and in the activation of regions involved in emotional regulation, such
as the prefrontal cortical areas [77]. Diminished connectivity between areas involved in top-down
control and areas involved in reactivity is also present. Furthermore, the activation of a frontoparietal
circuit has been shown to correlate negatively with the activation of the amygdala during reappraisal
of patients with BD type I. [78]. For these reasons, the study of the relation between cognition and
emotion is a central starting point to understand the development of mood symptoms. Currently,
there is growing interest in developing prevention strategies which have as primary outcome the
management or prevention of neurocognitive impairment in BD [79]. In this perspective, recent
literature has focused attention on the hypothetical positive effects of omega-3 polyunsaturated fatty
acids in patients with affective disorders [80]. Despite the great interest of researchers for n-3 PUFAs
and psychiatric diseases, just a few RCTs included neuropsychological evaluations or considered
cognition as an outcome. Specifically, we identified only three RCT studies exploring the effect of n-3
PUFA supplementation on neuropsychological performance in mood disorder patients (Table 1). In all
three studies, the authors did not find clear results; the score of neuropsychological assessments in
patients treated with n-3 PUFA was not statistically different than patients taking placebo. In particular,
two RCTs [81,82] explored the impact of n-3 PUFAs in a sample of depressed patients while the third
trial [83] on a sample of patients with subthreshold depressive symptoms. In the latter, the authors
have examined several neuropsychological domains using a standardized assessment in a cohort of 51
adults, taking EPA 1200 mg plus 800 mg DHA or placebo for a period of 12 weeks. They used the Trail
Making Test Part A (TMT-A) and Part B (TMT-B), the Ray Auditory Verbal Learning Test (RAVLT) and
the Delis Kaplan Executive Functioning System Stroop task in order to evaluate visuomotor speed,
verbal learning and memory, and executive functions. Interestingly, the authors found no difference
across all neuropsychological tests, in terms of performance, between the group taking n-3 PUFAs
and placebo. Similarly, Rogers et al. [81] found no significant cognitive effects of supplementation
with 630 mg EPA plus 850 mg DHA or placebo for 12 weeks in a larger sample of depressed patients
(n = 190). Patients were tested with a neuropsychological assessment using the Visual probe task,
the Simple reaction time, the Lexical decision, the Digit-symbol substitution, the Impulsivity score
and the N-Back task. Authors targeted speed information processing, reasoning, impulsivity, and
working memory. Finally, Antypa et al. [82] measured the cognitive performance of 71 depressed
patients with neutral and emotional information processing tasks, a Facial Expression Recognition
task and a Decision making (Gambling) task. Participants were treated with 1.74 g EPA plus 0.25 g
DHA for a period of four weeks. Overall, the results were inconclusive. Indeed, only a small n-3 PUFA
effect, though not statistically significant, was found on aspects of emotional decision-making and
no significant effect was observed on memory, attention and cognitive reactivity. On the contrary, it
is of note that the result of the Facial emotion recognition test in which the placebo group compared
to the n-3 PUFA group was found to have a higher rate of accuracy in recognizing fear over time.
This effect is not of trivial interpretation and deserves further investigation. In conclusion, no RCTs
administering only DHA supplementation as add-on therapy in mood disorders have been published
yet. However, we identified three RCTs on DHA combined with EPA supplementation in depressed
patients, without, though, providing statistically significant results on the therapeutic effect of Omega
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3 on cognitive performance. Therefore, it is necessary to provide clinical studies able to evaluate the
response of mood and cognitive function together.
3.3. DHA and ADHD
ADHD is a clinical disorder characterized by symptoms of inattention, hyperactivity, and
impulsivity [84]. ADHD is commonly diagnosed in childhood and has a high comorbidity with
other disorders of behavior and mood, such as conduct disorder and developmental coordination
disorder [85]. The worldwide prevalence of ADHD is estimated at 7.2% although there is significant
variability between countries that may be attributed to differences in methodology between studies,
such as diagnostic criteria [86]. The most common approaches to the treatment of ADHD are
medication, mainly with stimulant medications methylphenidate (MPH) and amphetamine, and/or
psychological or behavioral interventions [87]. However, not all children experience symptom
reduction after pharmacological treatment with MPH. Therefore, although the responder rate to
MPH is high (65–70%), supplementation with n-3 polyunsaturated fatty acids (n-3 PUFAs) might be
an option for non- responders or treatment-resistant children [88]. Clinical and biochemical evidence
suggests that functional deficiency of certain PUFAs could be related to ADHD. Children with ADHD
have been shown to have significantly lower plasma and blood concentrations of PUFA and, in
particular, lower levels of n-3 PUFA [89].
In this paragraph, we provide an update regarding the effects of n-3 PUFAs supplementation on
symptoms of ADHD in children. We identified five RCT studies (Table 1).
Milte et al. investigated the effects of a selective supplementation with EPA or DHA versus the n-6
PUFA linoleic acid (LA) on behavior, cognition, and literacy in children 7 to 12 years old with ADHD
symptoms [85].
A first analysis of results reported from the first four months of supplementation showed no
significant treatment effects for literacy or parent-reported behavior with the Conners Parent Rating
Scale (CPRS). Similarly, no significant treatment effects of DHA and EPA on the measurements of
attention or inhibition were observed.
The greatest benefit was observed in children who had comorbid learning difficulties: an increased
erythrocyte DHA over four months was associated with improved word reading and oppositional
behavior. In the 12-month study [90] the same authors found that changes in erythrocyte PUFA were
associated with improvements in literacy (word reading and spelling), attention (Sky Search and
Creature Counting), and behavior (subscales of parent-rated behavior through the CPRS). Particularly,
increases in erythrocyte EPA, DHA, and total n-3 PUFA and decreases in erythrocyte n-6 and the
n-6:n-3 ratio were associated with improvements.
The third work reported is a double-blind placebo-controlled intervention study carried out
by Widenhorn-Müller et al. [91], which investigated the effect of n-3 fatty acid supplementation on
behavior and cognition in children aged 6 to 12 years with ADHD. After 16 weeks of intervention,
the authors showed that supplementation with EPA/DHA improved working memory function in
the selected study population; however, no effects on other cognitive measures and parent- and
teacher-rated behavior were pointed out.
In the same year, Dean et al. [92] published the results of the first trial specifically designed to
assess the effects of fish oil supplementation on aggression in young people with impulsive aggressive
behaviors. In particular, aggressive behavior includes verbal abuse, property destruction, and physical
attacks and it can occur across a range of diagnoses, including disruptive behavior disorders, ADHD,
autism, and intellectual disabilities. The primary aim of this study was to assess the efficacy of n-3
fatty acids (EPA+DHA) for at least six months in the treatment of impulsive aggression in children
and adolescents aged 6–17 years with a diagnosis of a disruptive behavior disorder. The results
showed that fish oil supplementation for six weeks had no beneficial effects on various ratings of
aggressive behavior.
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Table 1. Randomized controlled trials (RCTs) of n-3 polyunsaturated fatty acids (PUFAs) supplementation in mood and neurodevelopmental disorders.
Study Diagnosis N. Sample N-PUFA Duration Neuropsychological Assessment Major Finding
[80] Mild to moderatelydepressed individuals 190
Three capsules/day
contained a total of
EPA 630 mg plus
DHA 850 mg
870 mg olive oil
mixed tocopherols 7.5 mg
orange oil 12 mg
Placebo treatment
contained a total of
Olive oil 2360 mg
mixed tocopherols 7.5 mg
orange oil 12 mg
12 weeks
Visual probe task. Simple reaction time.
Lexical decision. Digit-symbol substitution.
Impulsivity. N-Back.
No effects on cognitive function
after n-3 LCPUFA
supplementation.
[81] Recovered depressedindividuals 71
Three capsules/day
contained a total of
EPA 1.74 g
DHA 0.25 g
Placebo
olive oil
both of them lemon flavored
4 weeks
Neutral and emotional information
processing tasks.
Affective Go/No-Go task.
Attentional Go/No-Go task.
15 Words test.
Facial Expression Recognition task.
Decision-making (Gambling) task.
No significant effects were
observed on memory, attention,
cognitive reactivity and
depressive symptoms.
[82] Patients “at risk” formajor depression 51
Four capsules/day
contained a total of
EPA 1200 mg plus
DHA 800 mg
and one capsule of Sertraline
Placebo
4 capsules/day of paraffin 1000 mg and one
capsule of microcrystalline cellulose
12 weeks
Visuomotor speed (Trailmaking Test, Part
A).
Vebal learning and memory (The Rey
Auditory Verbal Learning Test (RAVLT))
Executive functions (Trailmaking Test,
Part B; Delis Kaplan Executive Functioning
System (DKEFS)) Stroop task
No significant changes in any
clinical or neuropsychological
measures were found.
[88,89]
Children with
attention-deficit/hyperactivity
disorder
70 [89];
90 [90]
4 × 500-mg
capsules/day EPA-rich fish oil:EPA 1109 mg and
DHA 108 mg
4 × 500-mg
capsules/day DHA-rich fish oil: EPA 264 mg and
DHA 1032 mg. Safflower oil (control):LA
1467 mg/day.
17 weeks [89],
52 weeks [90]
Literacy (Wechsler Individual Achievement
Test III); parent-rated behavior (Conners
Parent Rating Scale); different forms of
attention (Test of Everyday Attention for
Children)
No significant treatment effects
for literacy; parent-reported
behavior;
measurements of attention or
inhibition.
[90]
Children with
attention-deficit/hyperactivity
disorder
95 720 mg n-3 fatty acids (600 mg EPA, 120 mg DHA).Placebo (olive-oil) 16 weeks
Behavior (FBB ADHS parent-rated and
teacher-rated questionnaires, DIS- YPS-II;
German version of the Child Behavior
Check list; German version of the Teacher's
Report Form)
Significant improvement of
working memory function (Index
Score) when comparing the
EPA/DHA group with the
placebo-taking group.
[91]
Young people with
impulsive aggressive
behaviors.
21
400 mg EPA and 2000 mg
DHA
Placebo (low polyphenol
olive oil and 10 mg standard fish oil)
6 weeks
Aggressive behavior (The Children’s
Aggression Scale-Parent Version,
CAS-parent; The Modified Overt
Aggression Scale, MOAS)
No effect of treatment on
primary ratings of aggressive
behavior
[92]
Children with
attention-deficit/hyperactivity
disorder
50 500 mg algal DHAPlacebo (500 mg wheat germ oil) 26 weeks
Behavior (ADHD rating scale IV Parent
Version–Investigator)
No beneficial effect on the
symptoms of ADHD
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In conclusion, the most recent trial we report is by Crippa et al. [93] and, unlike the large majority
of studies that explored the efficacy of PUFA supplementation in ADHD using mixed n-3 fatty
acids, the aim of this research was to examine the effect of DHA supplementation as monotherapy
in children aged 7 to 14 with ADHD. In general, no superiority of DHA supplement to placebo
was observed on ADHD rating scale IV Parent Version–Investigator (ADHD-RS-IV), their a priori
primary outcome. DHA supplementation showed a significant, nonetheless quite limited, effect on the
hyperactivity–impulsivity scale and on total scores of the ADHD rating scale, with participants in both
groups showing improvements over the six months.
In conclusion, large high-quality RCTs are still required to further clarify the role of DHA on
functional outcomes in this population and to draw conclusions.
4. Discussion
The aim of this review was to provide a comprehensive overview of the effects of DHA on
cognition in severe psychiatric disorders (Table 2). We found a growing number of RCTs testing the
efficacy of n-3 PUFAs alone or as added therapy in the treatment of different psychiatric disorders.
However, only a handful of studies investigated the efficacy of DHA alone on cognitive function.
Indeed, the majority of RCTs on DHA focused on dementia or mild cognitive impairment [35,94].
Moreover, the small number of trials on cognitive impairment in psychiatric disorders show doubtful
and/or contrasting results, probably due to the heterogeneity of the methods employed by the original
studies, which often had small and inhomogeneous sample size, different selection criteria, different
neuropsychological batteries, different carriers and dosages of DHA (i.e., alone, or a combination of
DHA and EPA, or the addition of n-6 PUFAs) as well as various durations of supplementation.
Only partial positive effects on specific tasks of neurocognitive batteries in the most important
neuropsychiatric disorders have been shown, but even in this case the frequent lack of statistical
adjustment for multiple comparisons makes most reported results doubtful.
Table 2. Effects of n-3 PUFAs supplementation in mood and neurodevelopmental disorders: summary.
Diagnosis Positive Results Negative Results Positive Results withoutStatistical Significance
Mild to moderately depressed individuals [80]
Cognitive performance in the
impulsivity task might
be improved
Recovered depressed individuals [81]
Patients “at risk” for major depression [82]
Children with ADHD [89]
Children with ADHD [85]
Children with ADHD [90]
Young people with impulsive
aggressive behaviors [91]
Children with ADHD [92]
In some cases, it is probable that the detection and treatment of n-3 PUFAs deficiency needs
to be made early in the course of illness to exert a significant protection against the transition
to psychosis and severity of symptoms [95–97]. For psychotic disorders, we did not find RCTs
investigating the effect of DHA on cognition. Indeed, only two studies were conducted using
EPA alone and the results were conflicting. While Reddy et al. [62] demonstrated a significative
reduction in perseverative errors, which represents a key measure derived from the Wisconsin Card
Sort Test (WCST), Fenton et al. (2001) [63] found no significant effects of EPA on ameliorating cognitive
symptoms. However, these discordant results are due primarily to different designs of the study; one
is an open label while the other is a clinical randomized trial. Other factors justifying the results are
the different doses of EPA, different times of intervention, different sample sizes, different ages and
durations of illness of the samples.
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Most studies considered here are limited by a small sample size and future research (particularly
in the field of children with ADHD) should explore the consequences of n-3 PUFA supplementation in
improving school performance, which is not necessarily a clinically diagnosed developmental disorder.
For mood disorders, the reviewed studies have similar characteristics, all being quite
well-designed and implemented. However, the appropriate dose of DHA to administer and the
correct proportion between DHA and EPA [79] are still discussed. The heterogeneity of specific tests
represents a great methodological limit as well. Longer periods of study should be considered, as well as a
whole evaluation of clinical effects. [98–106]. The mechanism that binds mood, emotionality and cognitive
abilities is very complex and the underlying neuroactive circuits have been only partially explained so far.
The simultaneous lack of effect found on mood and cognition could suggest that these two aspects are
firmly associated with each other, so neither aspect can improve regardless of the other. In our opinion,
new research should take into consideration patients with different types of mood disorders.
Future clinical trials should be focused on the role of n-3 PUFA supplementation in protecting
neuropsychological functions, not only ameliorating psychiatric symptoms in patients treated with
standard psychiatric therapies (antipsychotic, antidepressant), prolonging clinical observations at
definitely longer terms.
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